
    
      To establish proof of concept regarding efficacy of an oral kappa agonist (KA), Pentazocine/
      Naloxone 50/0.5 mg, for the treatment of menopausal hot flashes.

      To gather data in support of a future proposal to study the safety and efficacy of a PRKA, a
      type of KA, for amelioration of menopausal hot flashes.
    
  